477 related articles for article (PubMed ID: 31288280)
1. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
2. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
3. Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis.
Mevius A; Brandes A; Hardtstock F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Digestion; 2021; 102(2):216-226. PubMed ID: 31639807
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
6. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Louis E; Litkiewicz M; Agboton C; Armuzzi A
United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
10. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
[TBL] [Abstract][Full Text] [Related]
13. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
Jossen J; Kiernan BD; Pittman N; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):304-309. PubMed ID: 31738290
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
16. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
17. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
18. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
19. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
